For gene therapy to work well, therapeutic molecules need to be efficiently delivered to the correct locations in the body -- a job commonly given to adeno-associated viruses (AAV). To improve the AAV ...
ENA Respiratory has raised US$22.4m (AU$34m) in Series B financing to support the phase 2 clinical development of its nasal ...
SAN FRANCISCO -- A new type of COVID-19 therapy is showing promise as a new tool to hijack the virus and slow down variants. It's a new weapon that could be added to the arsenal against COVID-19.
The next fight against COVID and the flu may be as simple as the spritz of a nasal spray containing non-drug ingredients already used in other similar products. Researchers at Harvard and Brigham and ...
Breakthroughs, discoveries, and DIY tips sent every weekday. Terms of Service and Privacy Policy. Researchers at Oxford announced today that a nasal spray version of ...
ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory infections, announces today that it has ...
A team of researchers at the Näär Lab at UC Berkeley have developed a new inhalable drug that blocks the viral replication of SARS-CoV-2 in lung cells. The drug is a type of antisense oligonucleotide, ...
Since the coronavirus enters the body through the nose, researchers have figured a nasal spray may be one way to defend against its spread. But developing an effective point-of-entry vaccine can be ...
Patients with chronic rhinosinusitis with nasal polyps and uncontrolled asthma experienced greater improvements in lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback